Stay updated on Durvalumab & Tremelimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.

Latest updates to the Durvalumab & Tremelimumab in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe page revision label was updated from v3.5.3 to v3.5.4, and the old AstraZeneca study locator contact block was removed.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page’s footer has updated the ClinicalTrials.gov interface revision/version from v3.5.2 to v3.5.3. This reflects a platform update rather than a change to the displayed study details.SummaryDifference0.0%

- Check29 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check51 days agoChange DetectedNapoli, Italy, 80131 was replaced with Naples, Italy, 80131 in the study locations.SummaryDifference0.0%

- Check58 days agoChange DetectedRevision metadata updated: added Revision: v3.5.0 and removed Revision: v3.4.3. No study details or participant information are affected.SummaryDifference0.0%

- Check65 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This is a minor technical update with no changes to study content or functionality.SummaryDifference0.0%

Stay in the know with updates to Durvalumab & Tremelimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.